Insight Molecular Diagnostics (IMDX) EBITDA Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted EBITDA Margin of 28390.62% for Q1 2026, down 1279.86% sequentially from 2057.51% in Q4 2025, and down 2807262.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) EBITDA Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported EBITDA Margin for 7 years, with the latest figure at 28390.62% in Q1 2026.
- Quarterly EBITDA Margin fell 2807262.0% year-over-year to 28390.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2311.95% (down 99416.0% YoY) and the FY2025 annual result came in at 1260.76%, up 198437.0% from the prior year.
- EBITDA Margin fell to 28390.62% in Q1 2026 per IMDX's latest filing, from 2057.51% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1969.7% in Q1 2023 and troughed at 28390.62% in Q1 2026.
- A 5-year average of 3355.85% and a median of 2057.51% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin surged 330037 bps in 2025, then sank 2807262 bps in 2026.
- Over 5 years, EBITDA Margin stood at 292.0% in 2022, then slumped by 934 bps to 3018.79% in 2023, then gained by 25 bps to 2262.92% in 2024, then gained by 9 bps to 2057.51% in 2025, then plunged by 1280 bps to 28390.62% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 28390.62%, 2057.51%, and 2525.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 17.99% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -10.07% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 11.58% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 34.98% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 31.97% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 12.10% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -4,770.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,770.71% |
| Mar 31, 2026 | -28,390.63% |
| Dec 31, 2025 | -2,057.51% |
| Sep 30, 2025 | -4,249.23% |
| Jun 30, 2025 | -1,900.00% |
| Mar 31, 2025 | -318.01% |
| Dec 31, 2024 | -2,262.92% |
| Sep 30, 2024 | -11,752.17% |
| Jun 30, 2024 | -4,760.58% |
| Mar 31, 2024 | -5,265.34% |
| Dec 31, 2023 | -5,152.55% |
| Sep 30, 2023 | -1,518.18% |
| Jun 30, 2023 | -1,791.36% |
| Mar 31, 2023 | 1,969.70% |
| Dec 31, 2022 | -1,371.97% |
| Sep 30, 2022 | -179.58% |
| Jun 30, 2022 | -88.85% |
| Mar 31, 2022 | -288.98% |
| Dec 31, 2021 | -994.15% |
| Sep 30, 2021 | -1,382.52% |